Pdot-Enabled Point-of-Care Digital PCR for Sensitive Detection of SARS-CoV-2

Information

  • Research Project
  • 10165078
  • ApplicationId
    10165078
  • Core Project Number
    R44GM126848
  • Full Project Number
    3R44GM126848-03S1
  • Serial Number
    126848
  • FOA Number
    PA-18-935
  • Sub Project Id
  • Project Start Date
    9/20/2017 - 7 years ago
  • Project End Date
    7/31/2021 - 3 years ago
  • Program Officer Name
    SAMMAK, PAUL J
  • Budget Start Date
    8/1/2019 - 5 years ago
  • Budget End Date
    7/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    03
  • Suffix
    S1
  • Award Notice Date
    7/13/2020 - 4 years ago
Organizations

Pdot-Enabled Point-of-Care Digital PCR for Sensitive Detection of SARS-CoV-2

Project Summary Current SARS-CoV-2 molecular diagnosis tests mostly are based on real-time quantitative PCR (qPCR). Digital PCR is a next-generation PCR technology based on limiting dilution, end-point PCR, and Poisson statistics. Digital PCR transforms the exponential, analog nature of qPCR quantification into a linear, digital signal quantification. Compared to qPCR, digital PCR offers several important advantages, including its ability to provide absolute quantification, tolerance to inhibitors/contaminants, and its high sensitivity. Two recent studies showed digital PCR has improved sensitivity for picking up COVID-19 that qPCR had missed. In addition, for some patients, results on SARS-CoV-2 infections from qPCR varied from day to day. But unlike qPCR, digital PCR showed consistent reproducible results. Overall, digital PCR was shown to reduce significantly false-negative results, which is particularly useful for diagnosing early or asymptomatic infections or for testing convalescent patients before discharge. Current fluorescent probes used in qPCR, such as FAM (a fluorescein dye), do not have the brightness to be visualized with a cell-phone type camera. To address this issue and to enable simple cell-phone readout of digital PCR results in a point-of-care setting, this project aims to develop Pdots into ultrabright probes for digital PCR assays that can provide sensitive detection of SARS-CoV-2.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    410204
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:410204\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    LAMPROGEN, INC.
  • Organization Department
  • Organization DUNS
    078456317
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981156005
  • Organization District
    UNITED STATES